Agency's New Drug Application approvals up 18% in '08

Share this article:
New drug approval reports seem to cast doubt on critics' charges that the FDA has raised the bar in obtaining drug approvals. NDA approvals are up 18% for the first half of the year compared with approvals during the same period in 2007, the agency said in July.

Through June 30, the FDA had approved 40 NDAs in 2008; at the same time last year only 34 had been approved. However, there was no change in new molecular entity (NME) approvals — for the first six month in 2007 and 2008 the agency approved seven NMEs in each period.

The FDA has been staunchly defending itself from industry complaints that, notwithstanding user-fee deadlines, it has found ways of exceeding them. The FDA suffers no penalty for failing to meet such deadlines.

Last year's FDA Amendments Act, passed with lobbying support from industry, added new approval-delaying burdens on the FDA's drug reviewers, especially with regard to safety concerns, says drugs director Janet Woodcock. She has given safety matters first priority as a result.

The 2008 first-half approval figures probably do not reflect the effects of the new law's demands. If so, the second half probably will—and based on Woodcock's statement, a reduction in approvals may be expected as the FDA gives even more attention to new-drug safety issues. This attention has resulted in the agency issuing more “non approvable” letters to sponsors, even in the face of unanimous advisory committee recommendations that a drug be approved.

“Why bother to have advisory committee meetings when the advice rendered is so often ignored?” asked analyst Ira Loss in a letter to clients. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets